For one of the rarest and most lethal kidney cancers—renal medullary carcinoma (RMC)—clinicians have historically lacked reliable tools to stage disease, guide treatment, and detect recurrence. A new institutional analysis now provides the most substantive evidence yet that FDG PET/CT imaging is not merely useful but near-universally sensitive in this cancer, potentially reshaping how these patients are managed from diagnosis through progression.
The study examined 49 patients with SMARCB1-deficient RMC who underwent [18F]FDG PET/CT as part of routine clinical care between 2016 and 2025. Forty-eight of the 49 patients demonstrated clearly FDG-avid disease, with the single non-avid case also showing no disease on conventional anatomic imaging—meaning PET/CT missed nothing that CT or MRI detected. Among the 23 patients imaged at baseline for initial staging, primary renal tumors were uniformly FDG-avid, with a median SUVmax of 13.4 and a median tumor-to-blood ratio of 10.7, indicating strong metabolic signal well above background. PET findings also altered treatment planning in a meaningful subset of cases, suggesting the modality adds clinically actionable information beyond standard cross-sectional imaging.
RMC is an exceptionally rare malignancy, almost exclusively affecting young patients with sickle cell trait, and carries a median survival often under a year. Its rarity has made prospective trials nearly impossible, and most guidance relies on case series. This 49-patient cohort, while still small in absolute terms, represents one of the largest RMC imaging datasets published to date. The finding that SUVmax values cluster at notably high levels (median 13.4) suggests robust glycolytic activity consistent with RMC's aggressive phenotype and SMARCB1 loss. A key limitation is the retrospective, single-institution design, which introduces referral bias and precludes standardized scan timing. Still, the near-100% detection rate positions FDG PET/CT as a strong candidate for inclusion in formal staging protocols for RMC—an incremental but genuinely meaningful advance for a cancer with very few evidence-based management tools.